Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI [FOX News]
SELLAS Life Sciences Group, Inc. (SLS)
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm
Check Earnings Report
US:NYSE Investor Relations:
sellaslifesciences.com/investors/overview/default.aspx
Company Research
Source: FOX News
SELLAS Life Sciences CEO Angelos Stergiou says his company is already on the cusp of a finalized leukemia vaccine, but another game-changer – personalized cancer vaccines – could be on the horizon, thanks to artificial intelligence. "I think it's going to be a revolutionary decade in medicine and in clinical research," he said Thursday on " Fox & Friends "Where AI comes into play is where it's going to allow us to do things expeditiously, and it's going to be more personalized. In other words, if you have a patient with a cancer, we can then use AI to do a genomic sequencing and, with the results, we can then either create a specific vaccine or treatment, or we can say this specific treatment will work for the patient." How long will the technology take to develop? Stergiou predicts the first of the specialized vaccines could come within the next three to four years. "It's very important to understand that if you put garbage into this algorithm, you'll get garbage out, so it'
Show less
Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLS alerts
High impacting SELLAS Life Sciences Group, Inc. news events
Weekly update
A roundup of the hottest topics
SLS
News
- Why SELLAS Life Sciences Group (SLS) Is Up 12.6% After Encouraging SLS009 Phase 2 AML Data And What's Next [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025GlobeNewswire
- SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual MeetingGlobeNewswire
SLS
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- SLS's page on the SEC website